TGFB1 and neoplasm: Increased secretion of TGF-β from tumors renders them more resistant to chemotherapy, whereas antagonizing TGF-β with neutralizing antibody or inhibitors can increase the chemotherapeutic sensitivity of tumor cells [13–16].